Related Experiment Video
Updated: Jul 13, 2025
08:10
An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
7.9K
Transient Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection in Proliferative Diabetic
Faizan Luqman1,2, Hafsa Bibi1,3, Marwa Mukhtar4,3
1Ophthalmology, Khyber Medical College, Peshawar, PAK.
Cureus
|October 18, 2023
Summary
Intravitreal bevacizumab (IVB) injections are generally safe for proliferative diabetic retinopathy (PDR) patients, showing minimal short-term intraocular pressure (IOP) changes. However, individuals with higher baseline IOP may require monitoring or prophylaxis.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Pharmacology
Background:
- Intravitreal bevacizumab (IVB) use is increasing for retinal ischemic diseases like proliferative diabetic retinopathy (PDR).
- Short-term and long-term complications of IVB are not well-established.
- This study investigates immediate intraocular pressure (IOP) fluctuations after IVB in PDR patients.
Purpose of the Study:
- To evaluate the safety of intravitreal bevacizumab (IVB) injections in patients with proliferative diabetic retinopathy (PDR).
- To assess short-term intraocular pressure (IOP) changes following IVB administration in PDR patients.
Main Methods:
- A prospective case series of 101 PDR patients undergoing IVB injection.
- Intraocular pressure (IOP) measured using Goldmann applanation tonometry (GAT) before and 30 minutes after IVB.
- Data analyzed using SPSS, with safety defined as IOP ≤20 mmHg 30 min post-injection.
Main Results:
- 90.1% of patients maintained an IOP ≤20 mmHg 30 minutes after IVB injection.
- Mean baseline IOP was 15.40±1.77 mmHg.
- No significant difference in safety was noted based on sex, age, or diabetes duration.
Conclusions:
- Intravitreal bevacizumab (IVB) injections demonstrate safety regarding immediate IOP changes in PDR patients.
- Patients with higher baseline IOP (>15 mmHg) have an increased risk of post-procedure IOP elevation.
- Prophylaxis may be considered for PDR patients with elevated baseline IOP undergoing IVB.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
459
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
459
01:25Glaucoma: Overview
599
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
599
01:28Angle Closure Glaucoma: Treatment
536
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
536